 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||
2 November 2004 | Volume 141 Issue 9 | Pages 693-704
Background: The role of angiotensin-receptor blockers (ARBs) in treating patients with chronic heart failure and high-risk acute myocardial infarction (MI) has been controversial, and recent clinical trials provide more information on this topic.
Purpose: To quantify the effect of ARBs when compared with placebo (with and without background angiotensin-converting enzyme [ACE] inhibitors) and ACE inhibitors on all-cause mortality and heart failure hospitalizations in patients with chronic heart failure and high-risk acute MI.
Data Sources: Data from original research published through 13 November 2003.
Study Selection: Predefined criteria were used to identify 24 trials.
Data Extraction: 2 reviewers independently collected information on study characteristics and data on all-cause mortality and heart failure hospitalization.
Data Synthesis: 24 trials involving 38 080 patients were included. Analysis of chronic heart failure trials revealed that 1) ARBs were associated with reduced all-cause mortality (odds ratio [OR], 0.83 [95% CI, 0.69 to 1.00]) and heart failure hospitalizations (OR, 0.64 [CI, 0.53 to 0.78]) as compared with placebo; 2) for ARBs versus ACE inhibitors, all-cause mortality (OR, 1.06 [CI, 0.90 to 1.26]) and heart failure hospitalization (OR, 0.95 [CI, 0.80 to 1.13]) did not differ; 3) and for combinations of ARBs plus ACE inhibitors versus ACE inhibitors alone, all-cause mortality was not reduced (OR, 0.97 [CI, 0.87 to 1.08]) but heart failure hospitalizations were reduced (OR, 0.77 [CI, 0.69 to 0.87]). For patients with high-risk acute MI, 2 randomized trials compared ARBs with ACE inhibitors but did not reveal differences in all-cause mortality or heart failure hospitalization.
Limitations: Comparative economic data between ARBs and ACE inhibitors are lacking.
Conclusions: Because ACE inhibitors and ARBs do not differ in efficacy for reducing all-cause mortality and heart failure hospitalizations in patients with chronic heart failure and in patients with high-risk acute MI, ARBs should be regarded as suitable alternatives to ACE inhibitors.
Author and Article Information
From Zynx Health Incorporated and Cedars-Sinai Health System, Los Angeles, California; David Geffen School of Medicine at the University of California, Los Angeles, Westwood, California; and Cerner Health Insights, Beverly Hills, California.
Acknowledgments: The authors thank Anacleto Gano Jr., MPH, for technical assistance in preparation of the manuscript and Cris Sevilla-Pappas for managing the reference database.
Grant Support: By a research grant from Cedars-Sinai Health System.
Potential Financial Conflicts of Interest: Stock ownership or options (other than mutual funds): D.C. Rhew (Merck, Pfizer); Grants received: Zynx Health Incorporated has received grants from AstraZeneca, Aventis, Bristol-Myers Squibb, Merck, Novartis, and Pfizer.
Requests for Single Reprints: Victor C. Lee, MD, Zynx Health Incorporated, 10880 Wilshire Boulevard, Suite 1450, Los Angeles, CA 90024; e-mail, vlee{at}zynx.com.
Current Author Addresses: Drs. Lee, Rhew, and Weingarten: Zynx Health Incorporated, 10880 Wilshire Boulevard, Suite 1450, Los Angeles, CA 90024.
Drs. Dylan and Badamgarav: Cerner Health Insights, 9100 Wilshire Boulevard, Suite 655E, Beverly Hills, CA 90212.
Dr. Braunstein: Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048. REVIEW
Meta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  F. H. Messerli The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J. Am. Coll. Cardiol., February 10, 2009; 53(6): 468 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ishii, T. Amano, T. Matsubara, and T. Murohara Pharmacological Intervention for Prevention of Left Ventricular Remodeling and Improving Prognosis in Myocardial Infarction Circulation, December 16, 2008; 118(25): 2710 - 2718. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Triplitt and C. A. Alvarez Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes Diabetes Spectr, July 1, 2008; 21(3): 177 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O. Phillips, A. Kashani, D. K. Ko, G. Francis, and H. M. Krumholz Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials Arch Intern Med, October 8, 2007; 167(18): 1930 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Keyhan, S.-F. Chen, and L. Pilote Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure Eur J Heart Fail, June 1, 2007; 9(6-7): 594 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hudson, E. Rahme, H. Behlouli, R. Sheppard, and L. Pilote Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure -- A population study Eur J Heart Fail, June 1, 2007; 9(6-7): 602 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Tsuyuki and M. A. McDonald Response to Tsuyuki and McDonald Circulation, August 22, 2006; 114(8): 855 - 860. [Full Text] [PDF]
|
|
|
|
 |
|
 C. M Ferrario Role of Angiotensin II in Cardiovascular Disease -- Therapeutic Implications of More Than a Century of Research Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1): 3 - 14. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A McDonald, S. H Simpson, J. A Ezekowitz, G. Gyenes, and R. T Tsuyuki Angiotensin receptor blockers and risk of myocardial infarction: systematic review BMJ, October 15, 2005; 331(7521): 873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H Lee Review: angiotension receptor blockers do not differ from ACE inhibitors in chronic heart failure or acute MI Evid. Based Med., June 1, 2005; 10(3): 76 - 76. [Full Text] [PDF]
|
|
|
|
|
|
N. K Hollenberg Spotlight on Renin: Therapeutic opportunities for renin inhibitors Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 107 - 109. [PDF]
|
|
|
|
 |
|
 M. J. Peeters and J. P. Tsikouris Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure Ann Intern Med, March 1, 2005; 142(5): 388 - 388. [Full Text] [PDF]
|
|
|
|
|
|
Correction: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction Ann Intern Med, March 1, 2005; 142(5): 391 - 391. [Full Text] [PDF]
|
|
|
|
|
|
M. B. McClellan, J. M. Loeb, C. M. Clancy, G. S. Francis, A. K. Jacobs, K. W. Kizer, M. E. O'Kane, and M. J. Wolk Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure Ann Intern Med, March 1, 2005; 142(5): 386 - 387. [Full Text] [PDF]
|
|
|
|
|
|
L. D. Regier and B. Jensen Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure Ann Intern Med, March 1, 2005; 142(5): 388 - 388. [Full Text] [PDF]
|
|
|
|
 |
|
 ARBs for Heart Failure and High-Risk MI: Meta-Analysis Journal Watch Cardiology, December 17, 2004; 2004(1217): 2 - 2. [Full Text]
|
|
Read all Rapid Responses
